Vor BioPharma has been granted a patent for genetically engineered hematopoietic cells with edited genes for cell-surface proteins, used in treating hematopoietic malignancies like acute myeloid leukemia. The method involves administering these cells along with agents targeting specific proteins. GlobalData’s report on Vor BioPharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Vor BioPharma Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Vor BioPharma, was a key innovation area identified from patents.

Genetically engineered hematopoietic cells for treating acute myeloid leukemia

Source: United States Patent and Trademark Office (USPTO). Credit: Vor BioPharma Inc

A recently granted patent (Publication Number: US11903973B2) outlines a method for treating hematopoietic malignancies, specifically acute myeloid leukemia (AML). The method involves administering genetically engineered hematopoietic cells (HCs) to a subject, where these cells are modified to have reduced or eliminated expression of CD33 and CD123 genes. Additionally, a therapeutically effective amount of an agent with anti-CD33 or anti-CD123 binding domains is also administered to the subject. The genetically engineered HCs are prepared using a CRISPR system and are capable of normal differentiation, expansion, and engraftment, making them a promising treatment option for AML.

Furthermore, the patent also describes a method for preparing a population of genetically engineered HCs by modifying the CD33 and CD123 genes in HCs obtained from a human subject. The modified HCs exhibit reduced or no binding to the anti-CD33 and anti-CD123 agents, ensuring targeted treatment of AML. The genetically engineered HCs retain their normal differentiation capacity and are capable of engraftment, making them a viable option for treating hematopoietic malignancies. The use of CRISPR technology in the genetic modification process enhances the precision and efficiency of the treatment, offering a potential breakthrough in the field of AML therapy.

To know more about GlobalData’s detailed insights on Vor BioPharma, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies